Inbios Reagents

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

CDC OFFICE OF ACQUISITION SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

96463

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6550

Additional Details
Set Aside

None

Place of Performance

Georgia, UNITED STATES

SourceSAM
The Centers for Disease Control and Prevention (CDC), operating under the Department of Health and Human Services, has issued a Special Notice indicating its intent to award a sole source, firm fixed price purchase order to InBios International, Inc. This procurement is specifically for the InBios DENV Detect TM IgM Capture ELISA Kit, which is the only serology test currently approved by the FDA for the diagnosis of dengue virus (DENV) infection. The acquisition of these kits is critical to the CDC’s ongoing DENV surveillance program, conducted at the Dengue Branch Diagnostic Laboratory. The primary objective of this procurement is to secure a reliable supply of FDA-approved diagnostic reagents essential for the accurate detection and monitoring of dengue cases. The InBios DENV Detect TM IgM Capture ELISA Kit is integral to the CDC’s public health mission, supporting timely and effective surveillance efforts that inform disease control strategies and public health responses. This action is being pursued as a sole source procurement under the authority of Revolutionary FAR Overhaul 6.103-1 (Simplified Acquisition Procedures), as InBios International, Inc. is the only known source capable of providing the required kits. The CDC has determined that no other products meet the stringent requirements for FDA approval and compatibility with the existing surveillance protocols. The procurement falls under NAICS Code 325413 (In-Vitro Diagnostic Substance Manufacturing), with a Product Service Code of 6550. The place of performance is Georgia, United States, where the CDC’s Dengue Branch Diagnostic Laboratory is located. While this notice is not a request for competitive quotations, the CDC will consider all quotations or responses received within 15 days of the notice’s issuance. Interested parties must submit their responses via email to the contract specialist, Iris Gonzalez, at [email protected], no later than March 27, 2026, before 5:00 PM EST. The government reserves the right to determine, at its sole discretion, whether to proceed with a competitive procurement based on the responses received. The contracting activity is managed by the CDC Office of Acquisition Services. Contractors evaluating this opportunity should note that the requirement is for a highly specialized, FDA-approved diagnostic reagent, and the procurement is expected to remain sole source unless a viable alternative is identified through the response process. For further details or to review the official notice, interested parties may refer to the SAM.gov opportunity at https://sam.gov/opp/0fe173bba2584460ae311cb8190cab13/view. Key Information: - Procuring Agency: Centers for Disease Control and Prevention (CDC), Office of Acquisition Services - Department: Health and Human Services - Product: InBios DENV Detect TM IgM Capture ELISA Kit - NAICS Code: 325413 (In-Vitro Diagnostic Substance Manufacturing) - PSC: 6550 - Place of Performance: Georgia, USA - Contact: Iris Gonzalez, [email protected] - Response Deadline: March 27, 2026, 5:00 PM EST - Notice Type: Special Notice (Sole Source) - Opportunity ID: 0fe173bba2584460ae311cb8190cab13 This procurement is essential to the CDC’s mission of safeguarding public health through effective dengue surveillance and response.